Rotigotine

CAS 99755-59-6 10 current recordsSmall Molecule

Who holds supplier records for Rotigotine? 10 organisations hold a current record for Rotigotine: an active US FDA Type II Drug Master File or a CEP. 6 of them hold a valid EU Certificate of Suitability. Recorded organisation countries for current records: India (4), China (2), Peru (1), Israel (1) and 2 other countries (2).

Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 16 Nov 2026. How we read these records

Cite as: PharmaTek, “Rotigotine: DMF and CEP holder records”, record as of 16 Nov 2026, pharmatek.co.uk/directory/api/rotigotine

Reading the evidence

  • 10 current records

    Several organisations hold current DMFs or CEPs. Whether any is a usable source for your grade, scale and market still needs qualification.

  • 4 with a company-level GMP certificate on record

    These organisations have at least one current EU or UK GMP certificate somewhere. It is not matched to the site that makes this substance; check the certificate's site and scope.

  • US product patents listed

    The latest patent listed in the FDA Orange Book for an approved product containing Rotigotine expires 1 Mar 2032. Product, formulation and method-of-use patents do not by themselves stop the ingredient being supplied or other products being approved.

Current records (10)

Organisations holding an active US FDA Type II Drug Master File or a CEP for Rotigotine. Country is the organisation's recorded country, not necessarily the manufacturing site.

Need Rotigotine sourced and checked?

The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.

Request sourcing help

Valid CEP holder entries (6)

Certificates of Suitability on the EDQM register for Rotigotine, including the salts, esters and hydrates the register lists separately; each row shows the substance as named on the certificate. A CEP confirms the substance can be controlled by the European Pharmacopoeia monograph; it is not a GMP certificate, and the holder is not necessarily the manufacturer.

HolderCountryCertificateIssuedEU GMP at holder's address
NEULAND LABORATORIES LIMITED HyderabadIN
CEP 2020-010 - Rev 05
Rotigotine, Form II
Jun 2026—
INTERQUIM S.A. Sant Cugat Del VallesES
CEP 2019-302 - Rev 03
Rotigotine
Apr 2026Inspected Sept 2024
Spain
OLON S.P.A. RodanoIT
CEP 2022-040 - Rev 01
Rotigotine, Polymorph II
Jul 2025Inspected Mar 2025
Italy
SHODHANA LABORATORIES PRIVATE LIMITED HyderabadIN
CEP 2024-265 - Rev 00
Rotigotine
Jul 2025—
WAVELENGTH ENTERPRISES LTD. Petah TikvaIL
CEP 2021-291 - Rev 02
Rotigotine
Oct 2024—
CHENGDU EASTON BIOPHARMACEUTICALS CO., LTD. ChengduCN
R0-CEP 2022-035 - Rev 00
Rotigotine
Aug 2023—

The GMP column shows the most recent EU GMP certificate issued for the same address as the holder, joined on the EMA location identifier printed on both documents (EudraGMDP, re-read about once a quarter; withdrawn certificates are excluded). A dash means no certificate carries that identifier, not that the site is uninspected. The holder's address is not necessarily where the substance is made.

Certification Online Database. European Directorate for the Quality of Medicines & HealthCare (EDQM), Council of Europe, (2026), URL: https://extranet.edqm.eu/publications/recherches_CEP.shtml. Accessed 16 Nov 2026. Reproduced with permission and unaltered. The EDQM and the Council of Europe accept no liability for any consequence arising from its use.

US product patents and exclusivity

The FDA Orange Book lists patents and exclusivities for specific approved products (6 listed products contain Rotigotine). The latest listed patent expires 1 Mar 2032. These dates are product-specific: they can cover a formulation, a combination or a method of use, and do not on their own show whether the ingredient is protected or whether generics are already approved. Check the individual product entries before planning a launch.

Overview

Rotigotine is a non-ergoline, dopamine agonist used in the treatment of Parkinson’s disease and restless legs syndrome. It functions as a transdermal patch to deliver continuous stimulation to dopamine receptors.

Chemical identity

IUPAC name
(6S)-6-[propyl(2-thiophen-2-ylethyl)amino]-5,6,7,8-tetrahydronaphthalen-1-ol
Canonical SMILES
CCCN(CCC1=CC=CS1)[C@H]2CCC3=C(C2)C=CC=C3O
InChIKey
KFQYTPMOWPVWEJ-INIZCTEOSA-N
Synonyms
Neupro API, leganto, neupro, spm 962, spm-962

Pharmacologic class

As the US FDA states it for this active substance on product listings.

Established pharmacologic class
Nonergot Dopamine Agonist
Mechanism of action
Dopamine Agonists

Therapeutic areas

NeurologyParkinson's DiseaseRestless Legs Syndrome

Record history

No change to the current records between 13 Nov 2026 and 16 Nov 2026.

Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week

What these records establish

  • An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
  • A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
  • Historical records show a past filing, not current supply.
  • Company GMP certificates are matched to the organisation, not to the site making this substance.
  • A substance missing from these registers is not evidence that no supplier exists.

Frequently asked questions

Which organisations hold current supplier records for Rotigotine?

10 organisations hold an active US FDA Type II Drug Master File or a CEP for Rotigotine: INTERQUIM SA (Peru), Neuland Laboratories Limited (India), WAVELENGTH ENTERPRISES LTD (Israel), MATRIX PHARMACORP PRIVATE LTD (India), Sichuan Qingmu Pharmaceutical Co., Ltd. (China), SOLARA ACTIVE PHARMA SCIENCES LTD (India), TAPI NL BV (Netherlands) and Chengdu EASTON Biopharmaceuticals Co., Ltd. (China), and 2 more listed on this page. A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.

Which Rotigotine Drug Master Files are active?

INTERQUIM SA (DMF 26481), Neuland Laboratories Limited (DMF 32684), WAVELENGTH ENTERPRISES LTD (DMF 26236), MATRIX PHARMACORP PRIVATE LTD (DMF 27370), Sichuan Qingmu Pharmaceutical Co., Ltd. (DMF 38363), SOLARA ACTIVE PHARMA SCIENCES LTD (DMF 37811) and TAPI NL BV (DMF 29468). The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.

Does Rotigotine have a European Certificate of Suitability?

Yes. 6 organisations hold a valid CEP for Rotigotine on the EDQM register, including NEULAND LABORATORIES LIMITED Hyderabad (IN), INTERQUIM S.A. Sant Cugat Del Valles (ES), OLON S.P.A. Rodano (IT), SHODHANA LABORATORIES PRIVATE LIMITED Hyderabad (IN), WAVELENGTH ENTERPRISES LTD. Petah Tikva (IL) and CHENGDU EASTON BIOPHARMACEUTICALS CO., LTD. Chengdu (CN). A CEP confirms the substance can be controlled by the European Pharmacopoeia monograph; it is not a GMP certificate, and the holder is not necessarily the manufacturer.

Does the FDA Orange Book list patents for products containing Rotigotine?

Yes. The latest patent listed for an approved US product containing Rotigotine expires 1 Mar 2032, across 6 listed products. These patents protect specific products, formulations or uses. They do not by themselves mean the ingredient is protected, and generic versions of other products may already be approved.

How do I qualify a Rotigotine supplier?

Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.

For suppliers

Do you supply Rotigotine?

Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.

Free. Payment never buys an evidence status.